The Report
Deep dives into company funding, growth strategies, and market insights from the world's most innovative businesses
189 reports and counting
Kailera Therapeutics Raises $400 Million in Series A - October 2024
Kailera Therapeutics announced $400 Million in Series A funding at a Undisclosed valuation. Kailera Therapeutics raised a massive $400 million Series A to develop clinical-stage injectable and oral therapies for chronic weight management and ...
Kailera Therapeutics raises $400M Series A at $1.5B valuation
Kailera Therapeutics raises $400M in Series A at $1.5B valuation. Developing obesity therapeutics with acquired pipeline...
Kailera Therapeutics Raises $400M in Series A
Kailera Therapeutics, a Biotech company based in Cambridge, MA, has raised $400M in Series A at a $1.5B valuation led by Atlas Venture, Bain Capital Life Sciences.
Kailera Therapeutics Raises $600M Series B to Transform Biotech
Kailera Therapeutics has secured $600M Series B in funding to accelerate growth and innovation in the biotech sector. Clinical-stage biopharmaceutical company developing novel obesity therapeutics targeting metabolic pathways...
Arnatar Therapeutics raises $52M Series A
Arnatar Therapeutics raises $52M in Series A. Developing therapeutics for autoimmune and inflammatory diseases...
Denali Therapeutics raises $217M Series C at $5B valuation
Denali Therapeutics raises $217M in Series C at $5B valuation. Neurodegeneration therapeutics...
Strand Therapeutics raises $153M Series B
Strand Therapeutics raises $153M in Series B. mRNA-based therapeutics developer with novel cancer treatment platform...
Seres Therapeutics raises $113M Series E at $450M valuation
Seres Therapeutics raises $113M in Series E at $450M valuation. Microbiome therapeutic platform...
Crystalys Therapeutics raises $205M Series B at $900M valuation
Crystalys Therapeutics raises $205M in Series B at $900M valuation. Developing novel therapeutics for neurodegenerative diseases...
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.